Deoxyshikonin
CAS No. : 43043-74-9
| Size | Price | Stock |
|---|---|---|
| 5mg | $160 | In-stock |
| 10 mg | Get quote | |
| 50 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N2187 |
| M.Wt: | 272.30 |
| Formula: | C16H16O4 |
| Purity: | >98 % |
| Solubility: | DMSO : 33.33 mg/mL (ultrasonic;warming;heat to 60°C) |
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL)[1][2][3].
In Vitro:Deoxyshikonin (6.25-100 μg/mL; 48 h) inhibits the growth of human colonic cancer cells[1].
Deoxyshikonin (25-100 μg/mL; 24, 48 h) induces early apoptotic cells death[1].
Deoxyshikonin (25-100 μg/mL; 48 h) leads to a dose-dependent increase in the percentage of cells at G0/G1 phase[1].
Deoxyshikonin (25-100 μg/mL; 48 h) exerts a decrease of PI3K, p-PI3K, Akt, p-Akt308 and mTOR proteins expression in HT29 and DLD-1 cell lines[1].
In Vivo:Deoxyshikonin (20 mg/kg; intraperitoneal injection; every two days for 13 days) markedly suppresses the growth of xenograft tumours on day 5, 9 and 11 with 20 mg/kg[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Deoxyshikonin
- Cat. No.:
- HY-N2187
- Quantity:
Your information is safe with us.